These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 15917644)

  • 21. [Proteasome inhibitors--new option in the treatment of tumor diseases].
    Spicka I; Klener P
    Cas Lek Cesk; 2004; 143(10):701-4. PubMed ID: 15584622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasome inhibitors: poisons and remedies.
    Meiners S; Ludwig A; Stangl V; Stangl K
    Med Res Rev; 2008 Mar; 28(2):309-27. PubMed ID: 17880010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 24. Position statement on the use of bortezomib in multiple myeloma.
    Morgan GJ; Davies FE; Cavenagh JD; Jackson GH; ;
    Int J Lab Hematol; 2008 Feb; 30(1):1-10. PubMed ID: 18190461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib as a potential treatment for prostate cancer.
    Papandreou CN; Logothetis CJ
    Cancer Res; 2004 Aug; 64(15):5036-43. PubMed ID: 15289299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].
    Tahmatzopoulos A; Gudegast C; Stöckle M; Wullich B; Unteregger G; Zwergel U; Zwergel T
    Aktuelle Urol; 2004 Nov; 35(6):491-6. PubMed ID: 15526229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience.
    Engel RH; Brown JA; Von Roenn JH; O'Regan RM; Bergan R; Badve S; Rademaker A; Gradishar WJ
    Cancer Invest; 2007 Dec; 25(8):733-7. PubMed ID: 17952740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
    Colson K; Doss DS; Swift R; Tariman J; Thomas TE
    Clin J Oncol Nurs; 2004 Oct; 8(5):473-80. PubMed ID: 15515281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
    Woodle ES; Alloway RR; Girnita A
    Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The proteasome--an emerging therapeutic target in cancer.
    Mitchell BS
    N Engl J Med; 2003 Jun; 348(26):2597-8. PubMed ID: 12826633
    [No Abstract]   [Full Text] [Related]  

  • 33. Proteasome inhibitors in lung cancer.
    Scagliotti G
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):177-89. PubMed ID: 16427303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of proteasome in pathophysiology of cancer cachexia].
    Wcisło G; Korniluk J; Wojtuń S
    Pol Merkur Lekarski; 2004; 17 Suppl 1():47-9. PubMed ID: 15603347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic].
    Spicka I; Hájek R; Vytrasová M; Maisnar V; Gregora E; Schutzova M; Straub J; Scudla V; Adam Z; Klener P
    Cas Lek Cesk; 2005; 144(9):636, 638-40. PubMed ID: 16193944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
    Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
    Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC; Farrell AT; Sridhara R; Pazdur R
    Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):509-10. PubMed ID: 12113081
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.